Author: argenx SE

$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative (“seronegative”) gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET AmRead More

Read More

Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/08:30 am EDT. To participate in the conference call or to watch the live webcast,Read More

Read More

Why Corteva’s restructuring plans are in focus Corteva (CTVA) is back on investors’ radar after its recent earnings report, where revenue came in below expectations and management outlined plans to separate the Seed and Crop Chemicals businesses. At the same time, UBS and JPMorgan downgraded the stock, pointing to execution risks around the breakup and a more cautious outlook. This is helping shape how the market is reassessing Corteva’s story right now. See our latest analysis for…Read More

Read More

Once again, the Washington State Cougars couldn’t hold onto a halftime lead and completely collapsed in the second half. In a game they needed to win to keep their hopes alive for that coveted four seed, they were outscored 43-27 in the second half by the Loyola Marymount Lions for a gut-punch 67-66 loss. The […]Read More

Read More